Genotyping in Sickle Cell Disease Patients: The French Strategy | Zendy

Aline Floch | Zendy; Christophe Tournamille | Zendy; Btissam Chami | Zendy; France Pirenne | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Genotyping in Sickle Cell Disease Patients: The French Strategy

Author(s) -

Aline Floch,

Christophe Tournamille,

Btissam Chami,

France Pirenne

Publication year - 2018

Publication title -

transfusion medicine and hemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.971

H-Index - 39

eISSN - 1660-3818

pISSN - 1660-3796

DOI - 10.1159/000490858

Subject(s) - genotyping , disease , medicine , intensive care medicine , genotype , genetics , biology , gene

This review presents the French strategy for blood group genotyping in high-responder and newly diagnosed sickle cell disease (SCD) patients. In addition to FY , JK , and MNS genotyping, the RH blood group system is now explored in SCD patients in France. Molecular typing has been used for the deduction of partial RH2 (C) antigens since 2010, and the gradual implementation of systematic RHD and RHCE genotyping nationwide was initiated in late 2014. In our laboratory, 962 RH:2 (C-positive) SCD patients have been tested since 2010, and 1,148 SCD patients of all RH phenotypes have been genotyped for clinically relevant alleles of RHD and RHCE since late 2014.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research